li001

Researchers have developed a new nanomaterial that destroys cancer cells by triggering a dual chemical attack inside tumors. The study, published in Advanced Functional Materials, improves chemodynamic therapy (CDT). Unlike traditional CDT agents that produce only one harmful molecule, this iron-based material generates both hydroxyl radicals and singlet oxygen. These highly reactive molecules damage DNA

Results from the phase 2 CYTOSHRINK trial show that adding Stereotactic Body Radiation Therapy (SBRT) to the immunotherapy combination of nivolumab and ipilimumab does not improve outcomes for patients with newly diagnosed advanced renal cell carcinoma (RCC). In fact, progression-free survival was shorter in the SBRT group (6.3 months) compared with immunotherapy alone (10.2 months).

Results from the LITESPARK-011 Phase 3 trial show that the combination of belzutifan (Welireg) and lenvatinib (Lenvima) is more effective than cabozantinib (Cabometyx) for patients with advanced clear cell renal cell carcinoma (ccRCC) previously treated with immunotherapy. The combination improved progression-free survival to 14.8 months compared with 10.7 months for cabozantinib, reducing the risk of disease progression or

Prostate cancer treatment has evolved from general hormone therapy to a personalized “ABCs + D” approach. While localized prostate cancer has a high 5-year survival rate, the focus is now on metastatic castration-resistant prostate cancer (mCRPC), which has historically had poor outcomes. Modern care emphasizes intensifying treatment earlier to achieve deeper responses. The “ABCs +

The Phase 3 SunRISE-2 study tested a new bladder drug-delivery system, Gem-iDRS, combined with the immunotherapy drug cetrelimab, in patients with muscle-invasive bladder cancer (MIBC) who did not undergo bladder removal. Gem-iDRS releases chemotherapy directly into the bladder over several weeks, while the control group received standard chemoradiotherapy (CRT), which combines radiation with systemic chemotherapy.

The RETAIN-1 and RETAIN-2 trials studied a new “risk-adapted” approach for treating muscle-invasive bladder cancer (MIBC). Instead of automatically removing the bladder with radical cystectomy, researchers wanted to find out which patients could safely keep their bladder through careful monitoring. In this approach, patients first received chemotherapy (MVAC) combined with immunotherapy (nivolumab) before surgery. Their